相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial
Johann Hitzler et al.
BLOOD (2021)
Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS)
Sina Al-Kershi et al.
KLINISCHE PADIATRIE (2021)
Clinical and biological aspects of myeloid leukemia in Down syndrome
Austin C. Boucher et al.
LEUKEMIA (2021)
Mapping the cellular origin and early evolution of leukemia in Down syndrome
Elvin Wagenblast et al.
SCIENCE (2021)
Pediatric relapsed acute myeloid leukemia: a systematic review
Anne E. Hoffman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome
Maurice Labuhn et al.
CANCER CELL (2019)
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
Mareike Rasche et al.
LEUKEMIA (2018)
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial
Jeffrey W. Taub et al.
BLOOD (2017)
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial
Madita Uffmann et al.
BLOOD (2017)
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan
Takashi Taga et al.
PEDIATRIC BLOOD & CANCER (2016)
How I treat paediatric relapsed acute myeloid leukaemia
Gertjan Kaspers
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Alan S. Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome
Johann K. Hitzler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
The landscape of somatic mutations in Down syndrome-related myeloid disorders
Kenichi Yoshida et al.
NATURE GENETICS (2013)
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
Michael R. Loken et al.
BLOOD (2012)
Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome
Takashi Taga et al.
BLOOD (2012)
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971
April D. Sorrell et al.
CANCER (2012)
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971
Alan S. Gamis et al.
BLOOD (2011)
Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial
Brenda E. S. Gibson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Continuous and High-Dose Cytarabine Combined Chemotherapy in Children with Down Syndrome and Acute Myeloid leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group (JCCLSG) AML 9805 Down Study
Takashi Taga et al.
PEDIATRIC BLOOD & CANCER (2011)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
Jan-Henning Klusmann et al.
BLOOD (2008)
Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with down syndrome and acute myeloid leukemia: The Japanese childhood AML cooperative study group
Kazuko Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature
Lotte Abildgaard et al.
ANNALS OF HEMATOLOGY (2006)
Increased age at diagnosis has a significantly negative effect on outcome in children with down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891
AS Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21
L Rainis et al.
BLOOD (2003)
GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome
JK Hitzler et al.
BLOOD (2003)
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
J Wechsler et al.
NATURE GENETICS (2002)
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
CM Zwaan et al.
BLOOD (2002)
Risks of leukaemia and solid tumours in individuals with Down's syndrome
H Hasle et al.
LANCET (2000)
分享论文
